{"id":"placebo-for-atezolizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reaction"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL3707227","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"As a placebo, it does not interact with any biological molecules or systems. It is used as a control in clinical trials to compare the efficacy of active treatments.","oneSentence":"This is a placebo, meaning it has no active therapeutic effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:58.019Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT04660344","phase":"PHASE3","title":"A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-05-03","conditions":"Muscle-invasive Bladder Cancer","enrollment":761},{"nctId":"NCT04873362","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-05-04","conditions":"Breast Cancer","enrollment":1188},{"nctId":"NCT04665856","phase":"PHASE3","title":"Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-12-21","conditions":"Small Cell Lung Carcinoma","enrollment":123},{"nctId":"NCT04619797","phase":"PHASE2, PHASE3","title":"A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-12-15","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":542},{"nctId":"NCT04256421","phase":"PHASE3","title":"A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-02-04","conditions":"Small Cell Lung Cancer","enrollment":490},{"nctId":"NCT03456063","phase":"PHASE3","title":"A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-04-24","conditions":"Non-Small-Cell Lung","enrollment":453},{"nctId":"NCT03199885","phase":"PHASE3","title":"Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-05","conditions":"Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma, Recurrent Breast Adenocarcinoma","enrollment":190},{"nctId":"NCT03371017","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-01-11","conditions":"Triple Negative Breast Neoplasms","enrollment":595},{"nctId":"NCT04540211","phase":"PHASE3","title":"A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-10-30","conditions":"Esophageal Cancer","enrollment":461},{"nctId":"NCT05377034","phase":"PHASE2","title":"Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients","status":"RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2022-10-26","conditions":"Locally Advanced Hepatocellular Carcinoma","enrollment":100},{"nctId":"NCT03271372","phase":"PHASE3","title":"Adjuvant Avelumab in Merkel Cell Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2017-12-19","conditions":"Stage III Merkel Cell Carcinoma AJCC v8, Stage IIIB Merkel Cell Carcinoma AJCC v8, Stage IIIA Merkel Cell Carcinoma AJCC v8","enrollment":101},{"nctId":"NCT04740918","phase":"PHASE3","title":"A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2021-06-07","conditions":"Metastatic Breast Cancer","enrollment":96},{"nctId":"NCT05690048","phase":"PHASE2","title":"Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)","status":"RECRUITING","sponsor":"Michael Dill","startDate":"2025-07-16","conditions":"Immunotherapy, HCC - Hepatocellular Carcinoma","enrollment":48},{"nctId":"NCT05224141","phase":"PHASE3","title":"Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-03-24","conditions":"Small Cell Lung Carcinoma","enrollment":460},{"nctId":"NCT03603184","phase":"PHASE3","title":"Atezolizumab Trial in Endometrial Cancer - AtTEnd","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2018-10-02","conditions":"Endometrial Cancer","enrollment":549},{"nctId":"NCT04996017","phase":"PHASE3","title":"Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)","status":"RECRUITING","sponsor":"Gruppo Oncologico Italiano di Ricerca Clinica","startDate":"2021-12-14","conditions":"Mesotheliomas Pleural","enrollment":162},{"nctId":"NCT03726879","phase":"PHASE3","title":"A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-01-11","conditions":"Breast Cancer","enrollment":454},{"nctId":"NCT03452137","phase":"PHASE3","title":"A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2018-04-03","conditions":"Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)","enrollment":406},{"nctId":"NCT04194203","phase":"PHASE3","title":"A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-04-09","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":305},{"nctId":"NCT04677504","phase":"PHASE2","title":"A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-02-23","conditions":"Biliary Tract Cancer","enrollment":162},{"nctId":"NCT05240131","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Galecto Biotech AB","startDate":"2022-03-15","conditions":"Non-Small Cell Lung Cancer","enrollment":88},{"nctId":"NCT03281954","phase":"PHASE3","title":"Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo","status":"ACTIVE_NOT_RECRUITING","sponsor":"NSABP Foundation Inc","startDate":"2017-12-19","conditions":"Triple Negative Breast Cancer","enrollment":1550},{"nctId":"NCT04177108","phase":"PHASE3","title":"A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-11-25","conditions":"Triple-Negative Breast Cancer","enrollment":242},{"nctId":"NCT03125902","phase":"PHASE3","title":"A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-08-25","conditions":"Triple-Negative Breast Cancer","enrollment":653},{"nctId":"NCT03197935","phase":"PHASE3","title":"A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-07-24","conditions":"Triple-negative Breast Cancer","enrollment":333},{"nctId":"NCT03024996","phase":"PHASE3","title":"A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2017-01-03","conditions":"Renal Cell Carcinoma","enrollment":778},{"nctId":"NCT05834413","phase":"NA","title":"Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2023-05-01","conditions":"Lung Cancer","enrollment":367},{"nctId":"NCT02322814","phase":"PHASE2","title":"A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2015-03-12","conditions":"Breast Cancer","enrollment":169},{"nctId":"NCT03038100","phase":"PHASE3","title":"A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-03-08","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms","enrollment":1301},{"nctId":"NCT02425891","phase":"PHASE3","title":"A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-06-23","conditions":"Triple Negative Breast Cancer","enrollment":902},{"nctId":"NCT03029832","phase":"PHASE2","title":"A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2017-04-27","conditions":"Urothelial Carcinoma","enrollment":5}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":147,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo for Atezolizumab","genericName":"Placebo for Atezolizumab","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo, meaning it has no active therapeutic effect. Used for Non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}